Name: Cardinal Health Y Tubing Connector,Fits tubing from 6 to 15mm, Sterile,15/Pack,366
Brand: CARDINAL HEALTH
SKU: 32846-171742
Price: 30.44 USD
Availability: InStock

Cardinal Health Y Tubing Connector,Fits tubing from 6 to 15mm, Sterile,15/Pack,366 - 32846-171742

By CARDINAL HEALTH

$30.44

(543 Reviews)

Model

32846-171742

Store

Health Products For You

Manufacturer

CARDINAL HEALTH

Detail

Cardinal Health Y Tubing Connector durable, shatter-resistant and can help reduce the expensive replacement cost associated with breakage. It is light in weight and sufficiently transparent to allow easy observation of flow. The connectors are for single use to save valuable reprocessing time.Cardinal Health Y Tubing Connector Sizing1/4 connector fits suction tubing from 3/16 to 5/16 (5 to 8mm)3/8 connector fits tubing from 5/16 to 7/16 (8 to 11mm).

Category

Respiratory

Background There are limited data about the range of diseases, natural history, age-appropriate end-points and optimal care for children with pulmonary hypertension (PH), including the need for developing high-quality patient registries of children with diverse forms of PH to enhance care and research. Our objective was to characterise the distribution and clinical features of diseases associated with paediatric PH, including natural history, evaluation, therapeutic interventions and outcomes, as defined by the World Symposium on Pulmonary Hypertension (WSPH) classification. Methods 1475 patients were enrolled into a multisite registry across the Pediatric Pulmonary Hypertension Network (PPHNet), comprised of eight interdisciplinary PH programmes. Results WSPH Groups 1 (pulmonary arterial hypertension (PAH)) and 3 (lung or hypoxia-related PH) were the most common primary class...

>Read More

Rationale The diffusing capacity of the lung for carbon monoxide corrected for haemoglobin ( D LCOcor ) measures gas movement across the alveolar–capillary interface. We hypothesised that D LCOcor is a sensitive measure of injurious allograft processes disrupting this interface. Objectives To determine the prognostic significance of the D LCOcor trajectory on chronic lung allograft dysfunction (CLAD) and survival. Methods A retrospective analysis was conducted of all bilateral lung transplant recipients at a single centre, between January 1998 and January 2018, with one or more D LCOcor measurements. Low baseline D LCOcor was defined as the failure to achieve a D LCOcor >75% predicted. Drops in D LCOcor were defined as >15% below recent baseline. Results 1259 out of 1492 lung transplant recipients were included. The median (range) time to pea...

>Read More

Although mesenchymal stromal (stem) cell (MSC) administration attenuates sepsis-induced lung injury in pre-clinical models, the mechanism(s) of action and host immune system contributions to its therapeutic effects remain elusive. We show that treatment with MSCs decreased expression of host-derived microRNA (miR)-193b-5p and increased expression of its target gene, the tight junctional protein occludin (Ocln), in lungs from septic mice. Mutating the Ocln 3 untranslated region miR-193b-5p binding sequence impaired binding to Ocln mRNA. Inhibition of miR-193b-5p in human primary pulmonary microvascular endothelial cells prevents tumour necrosis factor (TNF)-induced decrease in Ocln gene and protein expression and loss of barrier function. MSC-conditioned media mitigated TNF-induced miR-193b-5p upregulation and Ocln downregulation in vitro . When administered in vivo , MSC-conditioned m...

>Read More

Background Recent World Health Organization guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to that of an all-oral regimen among patients with drug-resistant tuberculosis who received bedaquiline and/or delamanid as part of their multidrug regimen. Methods Patients with a positive baseline culture were included. 6-month culture conversion was defined as two consecutive negative cultures collected >15 days apart. We derived predicted probabilities of culture conversion and relative risk using marginal standardisation methods. Results Culture conversion was observed in 83.8% (5...

>Read More

Introduction Host lipids play important roles in tuberculosis (TB) pathogenesis. Whether host lipids at TB treatment initiation (baseline) affect subsequent treatment outcomes has not been well characterised. We used unbiased lipidomics to study the prospective association of host lipids with TB treatment failure. Methods A case–control study (n=192), nested within a prospective cohort study, was used to investigate the association of baseline plasma lipids with TB treatment failure among adults with pulmonary TB. Cases (n=46) were defined as TB treatment failure, while controls (n=146) were those without failure. Complex lipids and inflammatory lipid mediators were measured using liquid chromatography mass spectrometry techniques. Adjusted least-square regression was used to assess differences in groups. In addition, machine learning identified lipids with highest area unde...

>Read More

Background The clinical context for using blood eosinophil (EOS) counts as treatment–response biomarkers in asthma and COPD requires better understanding of EOS distributions and ranges. We describe EOS distributions and ranges published in asthma, COPD, control (non-asthma/COPD) and general populations. Methods We conducted a comprehensive literature review and meta-analysis of observational studies (January 2008 to November 2018) that included EOS counts in asthma, severe asthma, COPD, control and general populations. Excluded studies had total sample sizes <200, EOS as inclusion criterion, hospitalised population only and exclusively paediatric participants. Results Overall, 91 eligible studies were identified, most had total-population-level data available: asthma (39 studies), severe asthma (12 studies), COPD (23 studies), control (seven studies) and general popu...

>Read More

Background France implemented a high emergency lung transplantation (HELT) programme nationally in 2007. A similar programme does not exist in Canada. The objectives of our study were to compare health outcomes within France as well as between Canada and France before and after the HELT programme in a population with cystic fibrosis (CF). Methods This population-based cohort study utilised data from the French and Canadian CF registries. A cumulative incidence curve assessed time to transplant with death without transplant as competing risks. The Kaplan–Meier method was used to estimate post-transplant survival. Results Between 2002 and 2016, there were 1075 (13.0%) people with CF in France and 555 (10.2%) people with CF in Canada who underwent lung transplantation. The proportion of lung transplants increased in France after the HELT programme was initiated (4.5% versu...

>Read More

Product Details for 32846-171742